BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38569441)

  • 1. Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis.
    Fukuda Y; Uchida Y; Ando K; Manabe R; Tanaka A; Sagara H
    Respir Investig; 2024 May; 62(3):481-487. PubMed ID: 38569441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
    Kashizaki F; Chen H; Miyasaka A; Tsuchiya N; Yamada C; Okazaki S; Kaneko M; Kano T; Kameda Y; Kikuchi A; Yumoto K; Osawa H; Koizumi H; Takahashi K; Kaneko T
    Clin Lung Cancer; 2024 Jan; 25(1):e52-e57.e2. PubMed ID: 37932180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.
    Kawase S; Hattori N; Ishikawa N; Horimasu Y; Fujitaka K; Furonaka O; Isobe T; Miyoshi S; Hamada H; Yamane T; Yokoyama A; Kohno N
    Respir Res; 2011 Jul; 12(1):97. PubMed ID: 21791074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
    Qi WX; Sun YJ; Shen Z; Yao Y
    J Chemother; 2015 Feb; 27(1):40-51. PubMed ID: 24724908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pre-treatment with EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database.
    Okada N; Hamano H; Yagi K; Niimura T; Aizawa F; Goda M; Zamami Y; Kitahara T; Ishizawa K
    Int J Clin Pharmacol Ther; 2024 Feb; 62(2):69-76. PubMed ID: 37969096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
    Shi L; Tang J; Tong L; Liu Z
    Lung Cancer; 2014 Feb; 83(2):231-9. PubMed ID: 24332320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005).
    Kanaji N; Ichihara E; Tanaka T; Ninomiya T; Kozuki T; Ishikawa N; Nishii K; Shoda H; Yamaguchi K; Kawakado K; Toyoda Y; Inoue M; Miyatake N; Watanabe N; Inoue T; Mizoguchi H; Komori Y; Kojima K; Kadowaki N
    Lung; 2024 Feb; 202(1):63-72. PubMed ID: 38265672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
    Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
    Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
    Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
    Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
    Atagi S; Katakami N; Yoshioka H; Fukuoka M; Kudoh S; Ogiwara A; Imai M; Ueda M; Matsui S
    Clin Lung Cancer; 2013 Jul; 14(4):407-17. PubMed ID: 23490546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.
    Ohmori T; Yamaoka T; Ando K; Kusumoto S; Kishino Y; Manabe R; Sagara H
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study.
    Zhao M; Liu S; Xie R; Zhang J; Li J
    Expert Opin Drug Saf; 2023; 22(12):1309-1316. PubMed ID: 37551674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.
    Nasu S; Suzuki H; Shiroyama T; Tanaka A; Samejima Y; Kanai T; Noda Y; Morishita N; Okamoto N; Hirashima T
    Invest New Drugs; 2020 Dec; 38(6):1915-1920. PubMed ID: 32542461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
    Yoneda KY; Hardin KA; Gandara DR; Shelton DK
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S31-5. PubMed ID: 17239288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.